OR WAIT 15 SECS
Lonza Expands Service Platform to Viral Vaccines, Gene Therapy Vectors
Lonza (Basel, Switzerland) has entered the viral based–manufacturing market with its purchase of Vivante GMP Solutions, Inc. (Houston, TX). The acquisition advances Lonza’s strategy to broaden its biologics custom service offering for the growing viral vaccine and gene therapy markets.
Vivante is a custom manufacturing organization dedicated to producing GMP viral-based therapeutics. The company’s viral-vaccine production services will be enhanced by Lonza’s expertise in expression technologies and large-scale manufacturing platforms. Additionally, Vivante’s experience with preclinical through late-stage supply of viral vector–based products will compliment Lonza’s growing cellular and gene therapy process development and manufacturing capabilities.
Vivante’s employees have joined Lonza and will operate as Lonza’s viral-based therapeutics business.
Vivante operates a state-of-the-art GMP clean room facility including production and fill–finish capabilities, along with research and development and quality control operations. In addition to its GMP manufacturing service, Vivante offers process development and optimization, quality control analytical testing, and on- and off-site GMP product storage and distribution to clinical trial sites.